Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Summary

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.

Timeline

Start

2024-02-14

Primary completion

2027-01-29

Completion

2027-06

Drugs

Indications